The Science is There: Key Considerations for Stabilizing Viral Vector-Based Covid-19 Vaccines

Journal of Pharmaceutical Sciences, vol. 110, pp. 627–634

Authors 5

1. Daan J.A. Crommelin

   Utrecht University

   Affiliation as printed

   Department of Pharmaceutics, Faculty of Science, Utrecht University, Utrecht, the Netherlands

2. David B. Volkin

   University of Kansas

   Affiliation as printed

   Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS, USA

3. Karin H. Hoogendoorn
   Affiliation as printed

   Preclinical Services Cell & Gene Therapy, Lonza BV, Maastricht, the Netherlands

4. Anthony S. Lubiniecki
   Affiliation as printed

   AL Associates LLC, West Chester, PA, USA

5. Wim Jiskoot corresponding Aachen Division of BioTherapeutics, Leiden Academic Centre for Drug Research

   Leiden University

   Affiliation as printed

   Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands. Electronic address: w.jiskoot@lacdr.leidenuniv.nl

   Division of BioTherapeutics, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands